Literature DB >> 19667213

Progress and challenges in RNA interference therapy for Huntington disease.

Scott Q Harper1.   

Abstract

Huntington disease is an incurable, dominant neurodegenerative disorder caused by polyglutamine repeat expansion in the huntingtin protein. Reducing mutant huntingtin expression may offer a treatment for Huntington disease. RNA interference has emerged as a powerful method to silence dominant disease genes. As such, it is being developed as a prospective Huntington disease therapy. Here I discuss the current progress and important remaining challenges of RNA interference therapy for Huntington disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667213     DOI: 10.1001/archneurol.2009.180

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

Review 1.  Huntington's disease: progress toward effective disease-modifying treatments and a cure.

Authors:  Carl D Johnson; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

Review 2.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

3.  Replacement of huntingtin exon 1 by trans-splicing.

Authors:  Hansjörg Rindt; Pei-Fen Yen; Christina N Thebeau; Troy S Peterson; Gary A Weisman; Christian L Lorson
Journal:  Cell Mol Life Sci       Date:  2012-07-20       Impact factor: 9.261

Review 4.  Silencing human genetic diseases with oligonucleotide-based therapies.

Authors:  Tamara Martínez; Natalia Wright; Marta López-Fraga; Ana Isabel Jiménez; Covadonga Pañeda
Journal:  Hum Genet       Date:  2013-03-14       Impact factor: 4.132

Review 5.  Gene therapy in mouse models of huntington disease.

Authors:  Amber L Southwell; Paul H Patterson
Journal:  Neuroscientist       Date:  2011-04       Impact factor: 7.519

Review 6.  RNAi: a potential new class of therapeutic for human genetic disease.

Authors:  Attila A Seyhan
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

Review 7.  Research advances in amyotrophic lateral sclerosis, 2009 to 2010.

Authors:  Rebecca Traub; Hiroshi Mitsumoto; Lewis P Rowland
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

Review 8.  Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.

Authors:  Monica Nizzardo; Chiara Simone; Marianna Falcone; Giulietta Riboldi; Federica Rizzo; Francesca Magri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Cell Mol Life Sci       Date:  2011-11-18       Impact factor: 9.261

9.  Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.

Authors:  Mahmoud A Pouladi; Yuanyun Xie; Niels Henning Skotte; Dagmar E Ehrnhoefer; Rona K Graham; Jeong Eun Kim; Nagat Bissada; X William Yang; Paolo Paganetti; Robert M Friedlander; Blair R Leavitt; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2010-01-22       Impact factor: 6.150

Review 10.  RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.

Authors:  Jian Liu; Scott Q Harper
Journal:  Curr Gene Ther       Date:  2012-08       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.